Drug adherence in chronic kidney diseases and dialysis

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 39-44

  Burnier, Michel ^a   Pruijm, Menno ^a   Wuerzner, Gregoire ^a   Santschi, Valerie ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b University of Applied Sciences Western Lausanne   (Switzerland)

Author keywords

chronic kidney diseases; drugs; hyperparathyroidism; hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CALCIMIMETIC AGENT; CINACALCET; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D; VITAMIN D DERIVATIVE;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG DOSE INCREASE; END STAGE RENAL DISEASE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE PRACTITIONER; PATIENT COMPLIANCE; PHARMACIST; POLYPHARMACY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

HUMANS; MEDICATION ADHERENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84922428239     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu015     Document Type: Review

References (46)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
3. Stevens LA, Coresh J, Greene T et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
4. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007; 15: 257-263
5. Bartlett JA, Fath MJ, Demasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-nave HIV-infected adults. AIDS 2006; 20: 2051-2064
6. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-1096
7. Bailie GR, Eisele G, Liu L et al. Patterns of medication use in the RRICKD study: focus on medications with cardiovascular effects. Nephrol Dial Tranplant 2005; 20: 1110-1115
8. Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 2009; 14: 185-190
9. Tong A, Howell M, Wong G et al. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant 2011; 1: 344-354
10. Denhaerynck K, Dobbels F, Cleemput I et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int 2005; 18: 1121-1133
11. Karamanidou C, Clatworthy J, Weinman J et al. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrology 2008; 9: 2
12. Schmitt KE, Edie CF, Laflam P et al. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 2010; 32: 541-548
13. Muntner P, Judd SE, Krousel-Wood M et al. Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010; 56: 447-457
14. Burnier M, Wuerzner G, Struijker-Boudier H et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62: 218-225
15. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. AM J Kidney Dis 2004; 43(5 suppl): 1-290
16. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
17. Sarafidis pA, Li S, Chen SC et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Medicine 2008; 121: 332-340
18. Magacho EJC, Ribeiro LC, Chaoubah A et al. Adherence to drug therapy in kidney disease. Braz J Med Biol Res 2011; 44: 258-262
19. Tandon T, Sinha AD, Agarwal R. Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure. Nephrol Dial Transplant 2013; 28: 1562-1568
20. Verbeke F, Lindley E, Van Bortel L et al. A European Renal Best Practice (ERBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 2014; 29: 490-496
21. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-Analysis. Hypertension 2009; 53: 860-866
22. Neri L, Martini A, Andreucci VE et al. Regimen complexity and prescription adherence in dialysis patients. Am J Nephrol 2011: 34: 71-76
23. Cukor D, Rosenthal DS, Jindal RM et al. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int 2009; 75: 1223-1229
24. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
25. Blayney MJ, Tentori F. Trends and consequences of mineral bone disorder in haemodialysis patients: lessons from the Dialysis Outcomes and Practice Pattern Study (DOPPS). J Ren Care 2009; 35: 7-13
26. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033
27. Bhan I, Burnett-Bowie SA, Ye J et al. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010; 5: 460-467
28. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-Analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62
29. Fukagawa M, Komaba H, Kakuta T. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. Expert Opin Pharamcother 2013; 14: 863-871
30. Lee A, Song X, Khan J et al. Association of cinacalcet adherence and costs in patients on dialysis. J Med Econ 2011; 14: 798-804
31. Ogna VF, Pruijm M, Zweiacker C et al. Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study. Biomed Res Int 2013; doi:10.1155/2013/104892
32. Naderi SH, Bestwick JP,Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-Analysis on 376,162 patients. Am J Med 2012; 125: 882-7.e1
33. Thilly N, Boini S, Kessler M et al. Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study. J Eval Clin Pract 2009; 15: 121-128
34. Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; (2): CD007784
35. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G et al., ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
36. Van Zuilen AD, Bots ML, Dulger A et al. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 2012; 82: 710-717
37. Rifkin DE, Laws MB, RaoMet al. Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study. Am J Kidney Dis 2010; 56: 439-446
38. Burnier M, Brown RE, Ong SH et al. Issues in BP control and the potential role of single-pill combination therapies. Int J Clin Pract 2009; 63: 790-798
39. Wthrich RP, Chonchol M, Covic A et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 280-289
40. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012
41. Haynes RB, Ackloo E, Sahota N et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011
42. Mendelssohn DC. Coping with the CKD epidemic: the promise of multidisciplinary team-based care. Nephrol Dial Transplant 2005; 20: 10-12
43. Barrett BJ, Garg AX, Goeree R et al. A nurse-coordinated model of care vs usual care for stage chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1241-1247
44. Santschi V, Lord A, Berbiche D et al. Impact of collaborative and multidisciplinary care on management of hypertension in chronic kidney disease outpatients. J Pharm Health Serv Res 2011; 2: 79-87
45. Santschi V, Chiolero A, Burnand B et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-Analysis of randomized trials. Arch Intern Med 2011; 171: 1441-1453
46. Hopkins RB, Garg AX, Levin A et al. Cost-effectiveness analysis of a randomized trial comparing care models for chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1248-1257